Analyst consensus rating
ADMA Biologics Analyst Rating: none
Direct answer
ADMA Biologics's consensus rating is none.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $17.00.
Forecast evidence checked November 3, 2026.
Get free ADMA Biologics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $11.06
- Average price target
- $17.00
- High price target
- $21.00
- Low price target
- $12.00
- Low target gap
- +8.5%
- Target upside
- +53.7%
- High target gap
- +89.9%
- Target range width
- 81.4%
- Consensus rating
- none
- Analysts
- 4
- Evidence date
- November 3, 2026
- Valid through
- November 10, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for ADMA Biologics?
ADMA Biologics has a verified none consensus. The same dataset has an average price target of $17.00.
How far are ADMA Biologics's low and high targets from the recorded price?
The low target implies +8.5%, while the high target implies +89.9%.
How many analysts are included in ADMA Biologics's consensus?
The verified consensus includes 4 analysts.
How is ADMA Biologics's target upside or downside calculated?
The average target of $17.00 is divided by the recorded price of $11.06, then one is subtracted to produce +53.7%. This does not guarantee a future return.
When was ADMA Biologics's analyst forecast verified?
The data was verified on 2026-11-03. The dataset is valid through 2026-11-10.